One-Third of U.S. Adults Likely to Refuse a COVID-19 Vaccine
FRIDAY, Jan. 15, 2021 -- Roughly one-third of Americans say they will decline a COVID-19 vaccine, according to research published online Jan. 4 in Social Science & Medicine.
Timothy Callaghan, Ph.D., from Texas A&M University in College Station, and colleagues assessed vaccine intention among 5,009 U.S. adults (May 28 to June 8, 2020) participating in an online survey administered through the Lucid Marketplace survey platform.
The researchers found that 31.13 percent of respondents did not intend to pursue vaccination. The odds of COVID-19 vaccine refusal were significantly higher for Blacks, women, conservatives, individuals who intended to vote for President Trump in 2020, and individuals with high levels of religiosity. The strongest associations were seen among women, who were 71 percent more likely not to pursue vaccination, and Blacks, who were 41 percent more likely not to pursue vaccination. Each one-unit increase in worry about COVID-19 was associated with a 23 percent decrease in intention to refuse a vaccine, and individuals who reported being tested for COVID-19 were 68 percent less likely to refuse vaccination. The two most common reasons individuals gave for not pursuing a vaccination were because they do not think the vaccine will be safe (17.83 percent) or effective (15.55 percent).
"By identifying those most likely to refuse vaccination, public health experts can develop health messages targeted at encouraging vaccination among these groups," the authors write. "This approach could prove vital to improving uptake of a COVID-19 vaccine."
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
FRIDAY, March 5, 2021 -- The frequency of urgent or emergent vitreoretinal surgical procedures decreased during the COVID-19 pandemic, according to a study published online March...
FRIDAY, March 5, 2021 -- Twelve cases of delayed large local reactions to the mRNA-1273 vaccination against severe acute respiratory syndrome coronavirus 2 are described in a...
FRIDAY, March 5, 2021 -- A five-day course of ivermectin does not improve the time to resolution of symptoms compared with placebo for adults with mild COVID-19, according to a...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.